These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 11436120

  • 21. First trimester screening for Down's syndrome using maternal serum PAPP-A and free beta-hCG in combination with fetal nuchal translucency thickness.
    Biagiotti R, Brizzi L, Periti E, d'Agata A, Vanzi E, Cariati E.
    Br J Obstet Gynaecol; 1998 Aug; 105(8):917-20. PubMed ID: 9746387
    [Abstract] [Full Text] [Related]

  • 22. If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases.
    Marsk A, Grunewald C, Saltvedt S, Valentin L, Almström H.
    Acta Obstet Gynecol Scand; 2006 Aug; 85(5):534-8. PubMed ID: 16752230
    [Abstract] [Full Text] [Related]

  • 23. First trimester, second trimester, and integrated screening for Down's syndrome in China.
    Miao ZY, Liu X, Shi TK, Xu Y, Song QH, Tang SH.
    J Med Screen; 2012 Jun; 19(2):68-71. PubMed ID: 22653574
    [Abstract] [Full Text] [Related]

  • 24. Cross-trimester repeated measures testing for Down's syndrome screening: an assessment.
    Wright D, Bradbury I, Malone F, D'Alton M, Summers A, Huang T, Ball S, Baker A, Nix B, Aitken D, Crossley J, Cuckle H, Spencer K.
    Health Technol Assess; 2010 Jul; 14(33):1-80. PubMed ID: 20624355
    [Abstract] [Full Text] [Related]

  • 25. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
    Cicero S, Spencer K, Avgidou K, Faiola S, Nicolaides KH.
    Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
    [Abstract] [Full Text] [Related]

  • 26. Comparison of combined, biochemical and nuchal translucency screening for Down syndrome in first trimester in Northern Finland.
    Peuhkurinen S, Laitinen P, Honkasalo T, Ryynanen M, Marttala J.
    Acta Obstet Gynecol Scand; 2013 Jul; 92(7):769-74. PubMed ID: 23369035
    [Abstract] [Full Text] [Related]

  • 27. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
    [Abstract] [Full Text] [Related]

  • 28. Screening for Down's syndrome in the first trimester: combined risk calculation, methodology, and validation of a web-based system.
    Kublickas M, Crossley J, Aitken D.
    Acta Obstet Gynecol Scand; 2009 Jun; 88(6):635-8, 7p following 638. PubMed ID: 19330568
    [Abstract] [Full Text] [Related]

  • 29. Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a regional experience from Germany.
    Soergel P, Pruggmayer M, Schwerdtfeger R, Muhlhaus K, Scharf A.
    Fetal Diagn Ther; 2006 Jun; 21(3):264-8. PubMed ID: 16601335
    [Abstract] [Full Text] [Related]

  • 30. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
    Cicero S, Bindra R, Rembouskos G, Spencer K, Nicolaides KH.
    Prenat Diagn; 2003 Apr; 23(4):306-10. PubMed ID: 12673635
    [Abstract] [Full Text] [Related]

  • 31. The utility of circulating LHCGR as a predictor of Down's syndrome in early pregnancy.
    Chambers AE, Mills WE, Mercadé I, Crovetto F, Crispi F, Bodi LR, Pugia M, Mira A, Lasalvia L, Banerjee S, Casals E, Gratacos E.
    BMC Pregnancy Childbirth; 2014 Jun 06; 14():197. PubMed ID: 24906955
    [Abstract] [Full Text] [Related]

  • 32. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
    Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2008 May 06; 31(5):493-502. PubMed ID: 18432600
    [Abstract] [Full Text] [Related]

  • 33. Effect of first-trimester nuchal translucency on second-trimester maternal serum biochemical screening for Down's syndrome.
    Thilaganathan B, Slack A, Wathen NC.
    Ultrasound Obstet Gynecol; 1997 Oct 06; 10(4):261-4. PubMed ID: 9383877
    [Abstract] [Full Text] [Related]

  • 34. First-trimester combined ultrasound and biochemical screening for Down syndrome in routine clinical practice.
    Stenhouse EJ, Crossley JA, Aitken DA, Brogan K, Cameron AD, Connor JM.
    Prenat Diagn; 2004 Oct 06; 24(10):774-80. PubMed ID: 15503268
    [Abstract] [Full Text] [Related]

  • 35. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome.
    Wald NJ, Hackshaw AK.
    Prenat Diagn; 1997 Sep 06; 17(9):821-9. PubMed ID: 9316126
    [Abstract] [Full Text] [Related]

  • 36. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study.
    von Kaisenberg CS, Gasiorek-Wiens A, Bielicki M, Bahlmann F, Meyberg H, Kossakiewicz A, Pruggmayer M, Kamin G, Fritzer E, Harris C, Arnold N, German Speaking Down Syndrome Screening Group.
    J Matern Fetal Neonatal Med; 2002 Aug 06; 12(2):89-94. PubMed ID: 12420837
    [Abstract] [Full Text] [Related]

  • 37. Maternal weight and ethnic adjustment within a first-trimester Down syndrome and trisomy 18 screening program.
    Krantz DA, Hallahan TW, Macri VJ, Macri JN.
    Prenat Diagn; 2005 Aug 06; 25(8):635-40. PubMed ID: 16049986
    [Abstract] [Full Text] [Related]

  • 38. Increased time-to-pregnancy and first trimester Down's syndrome screening.
    Ranta JK, Raatikainen K, Romppanen J, Pulkki K, Heinonen S.
    Hum Reprod; 2010 Feb 06; 25(2):412-7. PubMed ID: 19945962
    [Abstract] [Full Text] [Related]

  • 39. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
    Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O.
    Ultrasound Obstet Gynecol; 2005 Mar 06; 25(3):221-6. PubMed ID: 15736186
    [Abstract] [Full Text] [Related]

  • 40. Comparison of serum markers in first-trimester down syndrome screening.
    Canick JA, Lambert-Messerlian GM, Palomaki GE, Neveux LM, Malone FD, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Saade GR, Berkowitz RL, Dar P, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, D'Alton ME, First and Second Trimester Evaluation of Risk (FASTER) Trial Research Consortium.
    Obstet Gynecol; 2006 Nov 06; 108(5):1192-9. PubMed ID: 17077242
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.